Perspective Therapeutics (CATX) vs CONMED (CNMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
CONMED (CNMD) has outperformed Perspective Therapeutics (CATX) over the past year, losing 2.2% versus a loss of 31.1%. Over five years, CATX leads with a -57.1% price change compared with -68.7% for CNMD. CONMED is the larger company by market cap ($1.33 billion vs $303.6 million), about 4.4 times the size.
CONMED pays a dividend yielding 0.45%, while Perspective Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | CNMD |
|---|---|---|
| Share price | $2.66 | $44.42 |
| Market cap | $303.64M | $1.33B |
| 1-day change | -1.85% | -1.53% |
| YTD return | -3.27% | +9.41% |
| 1-year return | -31.09% | -2.18% |
| 5-year return | -57.10% | -68.72% |
| P/E ratio (TTM) | — | 24.01 |
| Forward P/E | — | 9.29 |
| EPS (TTM) | $-1.33 | $1.85 |
| Dividend yield | 0.00% | 0.45% |
| Annual dividend | $0.00 | $0.20 |
| Revenue (latest FY) | — | $1.37B |
| Revenue growth (YoY) | — | +5.18% |
| Net income (latest FY) | — | $47.05M |
| Gross margin | — | 54.59% |
| Operating margin | — | 7.46% |
| Net margin | — | 3.42% |
| 52-week high | $6.16 | $53.66 |
| 52-week low | $1.96 | $31.44 |
| Distance from 52-week high | -56.82% | -17.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +362.03% | +2.43% |
| Average volume | 1.65M | 482.58K |
| Shares outstanding | 114.15M | 29.95M |
| Employees | 163 | 3,900 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CONMED is about 4.4 times larger than Perspective Therapeutics by market value ($1.33B vs $303.64M).
- CNMD has outperformed CATX by 28.9 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Healthcare · Medical Devices · 163 employees
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Healthcare · Medical Devices · 3,900 employees
CATX vs CNMD FAQ
Which is bigger, Perspective Therapeutics or CONMED?
CONMED (CNMD) is larger, with a market capitalization of $1.33B compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or CNMD?
CNMD returned -2.18% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perspective Therapeutics or CONMED?
CONMED pays a dividend yielding 0.45%, while Perspective Therapeutics does not currently pay a regular dividend.
Are Perspective Therapeutics and CONMED in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.